BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank100
Studio
Year-over-Year Change

Price-to-earnings ratio

Latest
6.20
↑ 186% vs avg
Percentile
P100
Near historical high
Streak
1 yr
Consecutive growthElevated
Average
-7.19
Historical baseline
PeriodValueYoY Change
20256.20+135.5%
2024-17.49-244.1%
2023-5.08+41.2%
2022-8.64+35.9%
2021-13.48-97.7%
2020-6.82-86.1%
2019-3.66+55.5%
2018-8.22-30.5%
2017-6.30+25.5%
2016-8.46-